Sensus Healthcare (SRTS)
(Delayed Data from NSDQ)
$6.29 USD
0.00 (0.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.28 -0.01 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.29 USD
0.00 (0.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.28 -0.01 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth F Momentum D VGM
Zacks News
Sensus Healthcare, Inc. (SRTS) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $5.90, representing a +1.72% change from its previous close.
All You Need to Know About Sensus Healthcare (SRTS) Rating Upgrade to Strong Buy
by Zacks Equity Research
Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sensus Healthcare, Inc. (SRTS) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) closed at $5.80 in the latest trading session, marking a -1.86% move from the prior day.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Sensus Healthcare, Inc. (SRTS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Sensus Healthcare, Inc. (SRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Sensus Healthcare, Inc. (SRTS) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why
by Zacks Equity Research
Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Think Sensus Healthcare (SRTS) Could Surge 65.68%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 65.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Sensus Healthcare (SRTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Sensus Healthcare, Inc. (SRTS) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Best Momentum Stocks to Buy for August 13th
by Zacks Equity Research
BLBD and SRTS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 13, 2024.
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 64.74%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 64.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for August 13th
by Zacks Equity Research
BLBD, SRTS, LAKE, MPW and NYT have been added to the Zacks Rank #1 (Strong Buy) List on August 13, 2024.
Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Sensus Healthcare (SRTS) delivered earnings and revenue surprises of 233.33% and 31.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Buying Great Under-the-Radar Stocks During the August Market Pullback
by Benjamin Rains
Investors who want to buy stocks in August might consider searching for stocks gaining more attention from Wall Street. Today we dive into Sensus Healthcare (SRTS) stock and more.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 5.88% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 25.81% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.25, representing a -1.88% change from its previous close.
Hologic (HOLX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 3.92% and 1.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why
by Zacks Equity Research
Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Sensus Healthcare, Inc. (SRTS) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $6.42, moving -0.47% from the previous trading session.